[바이오사 리포트] 씨젠, 비호흡기서 마진 회복세…밸류업 발판 1분기

Seegene's successful pivot to non-respiratory diagnostic products marks a critical transition from pandemic-dependent growth to a sustainable, high-margin business model. The integration of digital transformation and PCR automation through strategic acquisitions positions the company to lead the next generation of diagnostics beyond traditional respiratory testing. This recovery serves as a foundational milestone for their Corporate Value-up initiative, signaling a return to normalized profitability.